GO
Loading...

Gilead Sciences Inc

More

  • Jan 30- U.S. drugmaker AbbVie Inc's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent. Excluding the charge and other special items, AbbVie earned 89 cents per share. Sales of Humira, which AbbVie inherited from Abbott Laboratories in 2013, rose to $3.36 billion in the fourth quarter ended...

  • The North Chicago- based company's full results were weighed down by a $2.2 billion breakup fee and other expenses from its abandoned merger with Shire PLC. AbbVie had envisioned buying Shire and reincorporating on the British island of Jersey, where Shire is incorporated. But AbbVie's board got cold feet after the U.S. government created new limitations on...

  • UPDATE 1-U.S. FDA approves Bristol-Myers, J&J HIV pills Thursday, 29 Jan 2015 | 6:35 PM ET

    Jan 29- The U.S. Food and Drug Administration on Thursday approved two fixed-dose HIV pills that combine protease inhibitors- one made by Bristol-Myers Squibb Co and the other by Johnson& Johnson- both with a boosting agent produced by Gilead Sciences Inc.. Bristol-Myers said its drug, Evotaz, is a once-daily pill containing Reyataz, also known as atazanavir, a...

  • Final Glance: Biotechnology companies Thursday, 29 Jan 2015 | 6:14 PM ET

    Amgen Inc. rose $1.73 or 1.1 percent, to $156.37. Biogen Idec rose $2.07 or. 6 percent, to $353.25. Gilead Sciences Inc. rose $1.73 or 1.7 percent, to $104.18.

  • U.S. FDA approves Bristol-Myers' HIV drug Thursday, 29 Jan 2015 | 5:44 PM ET

    Jan 29- The U.S. Food and Drug Administration has approved the sale of Evotaz, a once-daily combination pill to treat HIV made by Bristol-Myers Squibb Co, the company said on Thursday. The new drug combines Reyataz, also known as atazanavir, a Bristol-Myers' protease inhibitor, with cobicistat, a boosting agent produced by Gilead Sciences Inc..

  • Early Glance: Biotechnology companies Thursday, 29 Jan 2015 | 10:40 AM ET

    Amgen Inc. rose $1.54 or 1.0 percent, to $156.18. Biogen Idec fell $3.18 or. 9 percent, to $348.01. Celgene Corp. fell$. 72 or. 6 percent, to $118.25.

  • Final Glance: Biotechnology companies Wednesday, 28 Jan 2015 | 6:07 PM ET

    Amgen Inc. fell $4.25 or 2.7 percent, to $154.64. Biogen Idec fell $6.71 or 1.9 percent, to $351.18. Celgene Corp. fell $3.39 or 2.8 percent, to $118.97.

  • Midday Glance: Biotechnology companies Wednesday, 28 Jan 2015 | 1:21 PM ET

    Amgen Inc. fell $2.09 or 1.3 percent, to $156.80. Biogen Idec fell $1.77 or. 5 percent, to $356.12. Celgene Corp. fell $1.71 or 1.4 percent, to $120.65.

  • Early Glance: Biotechnology companies Wednesday, 28 Jan 2015 | 10:41 AM ET

    Amgen Inc. fell$. 60 or. 4 percent, to $158.29. Biogen Idec fell$. 64 or. 2 percent, to $357.25. Celgene Corp. fell$. 13 or. 1 percent, to $122.23.

  • Final Glance: Biotechnology companies Tuesday, 27 Jan 2015 | 6:08 PM ET

    Amgen Inc. fell$. 84 or. 5 percent, to $158.89. Biogen Idec fell $4.55 or 1.3 percent, to $357.89. Celgene Corp. fell $1.76 or 1.4 percent, to $122.36.

  • Midday Glance: Biotechnology companies Tuesday, 27 Jan 2015 | 1:36 PM ET

    Amgen Inc. fell$. 17 or. 1 percent, to $159.57. Biogen Idec fell $2.29 or. 6 percent, to $360.15. Celgene Corp. fell$. 81 or. 7 percent, to $123.31.

  • Early Glance: Biotechnology companies Tuesday, 27 Jan 2015 | 10:25 AM ET

    Amgen Inc. fell$. 82 or. 5 percent, to $158.91. Biogen Idec rose$. 02 or percent, to $362.46. Celgene Corp. fell$. 68 or. 5 percent, to $123.44.

  • Final Glance: Biotechnology companies Monday, 26 Jan 2015 | 6:04 PM ET

    Amgen Inc. fell$. 08 or. 1 percent, to $159.73. Biogen Idec rose $4.91 or 1.4 percent, to $362.44. Celgene Corp. rose$. 23 or. 2 percent, to $124.12.

  • Jan 26- Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus. EnvisionRx said Gilead's Sovaldi and its newer two-drug...

  • Midday Glance: Biotechnology companies Monday, 26 Jan 2015 | 1:53 PM ET

    Amgen Inc. rose$. 26 or. 2 percent, to $160.07. Biogen Idec rose $3.25 or. 9 percent, to $360.78. Celgene Corp. rose$. 16 or. 1 percent, to $124.05.

  • Early Glance: Biotechnology companies Monday, 26 Jan 2015 | 12:16 PM ET

    Amgen Inc. fell$. 98 or. 6 percent, to $158.83. Biogen Idec fell$. 29 or. 1 percent, to $357.24. Celgene Corp. fell$. 56 or. 5 percent, to $123.33.

  • Final Glance: Biotechnology companies Friday, 23 Jan 2015 | 6:04 PM ET

    Amgen Inc. rose$. 24 or. 2 percent, to $159.81. Biogen Idec rose $3.88 or 1.1 percent, to $357.53. Celgene Corp. rose$. 18 or. 1 percent, to $123.89.

  • Midday Glance: Biotechnology companies Friday, 23 Jan 2015 | 1:31 PM ET

    Amgen Inc. fell$. 45 or. 3 percent, to $159.12. Biogen Idec rose $4.60 or 1.3 percent, to $358.25. Celgene Corp. rose$. 04 or percent, to $123.75.

  • Early Glance: Biotechnology companies Friday, 23 Jan 2015 | 11:24 AM ET

    Amgen Inc. fell$. 51 or. 3 percent, to $159.07. Biogen Idec rose $2.25 or. 6 percent, to $355.90. Celgene Corp. fell$. 73 or. 6 percent, to $122.98.

  • Final Glance: Biotechnology companies Thursday, 22 Jan 2015 | 6:05 PM ET

    Amgen Inc. rose $2.19 or 1.4 percent, to $159.57. Biogen Idec fell $8.18 or 2.3 percent, to $353.65. Celgene Corp. rose $1.49 or 1.2 percent, to $123.71.